1. Home
  2. MCRB vs MSW Comparison

MCRB vs MSW Comparison

Compare MCRB & MSW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MCRB
  • MSW
  • Stock Information
  • Founded
  • MCRB 2010
  • MSW 2012
  • Country
  • MCRB United States
  • MSW Hong Kong
  • Employees
  • MCRB N/A
  • MSW N/A
  • Industry
  • MCRB Biotechnology: Pharmaceutical Preparations
  • MSW
  • Sector
  • MCRB Health Care
  • MSW
  • Exchange
  • MCRB Nasdaq
  • MSW NYSE
  • Market Cap
  • MCRB 72.0M
  • MSW 62.8M
  • IPO Year
  • MCRB 2015
  • MSW 2024
  • Fundamental
  • Price
  • MCRB $7.63
  • MSW $4.31
  • Analyst Decision
  • MCRB Hold
  • MSW
  • Analyst Count
  • MCRB 4
  • MSW 0
  • Target Price
  • MCRB $73.67
  • MSW N/A
  • AVG Volume (30 Days)
  • MCRB 75.0K
  • MSW 129.6K
  • Earning Date
  • MCRB 08-12-2025
  • MSW 07-01-2025
  • Dividend Yield
  • MCRB N/A
  • MSW N/A
  • EPS Growth
  • MCRB N/A
  • MSW 18.78
  • EPS
  • MCRB 8.98
  • MSW 0.20
  • Revenue
  • MCRB N/A
  • MSW $31,769,612.00
  • Revenue This Year
  • MCRB N/A
  • MSW N/A
  • Revenue Next Year
  • MCRB N/A
  • MSW N/A
  • P/E Ratio
  • MCRB $0.89
  • MSW $21.09
  • Revenue Growth
  • MCRB N/A
  • MSW 30.91
  • 52 Week Low
  • MCRB $6.53
  • MSW $2.12
  • 52 Week High
  • MCRB $30.60
  • MSW $10.58
  • Technical
  • Relative Strength Index (RSI)
  • MCRB 48.66
  • MSW N/A
  • Support Level
  • MCRB $7.25
  • MSW N/A
  • Resistance Level
  • MCRB $7.89
  • MSW N/A
  • Average True Range (ATR)
  • MCRB 0.46
  • MSW 0.00
  • MACD
  • MCRB 0.11
  • MSW 0.00
  • Stochastic Oscillator
  • MCRB 60.23
  • MSW 0.00

About MCRB Seres Therapeutics Inc.

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

About MSW MING SHING GROUP HOLDINGS LIMITED

Ming Shing Group Holdings Ltd is a holding company, which is primarily operated through its indirectly wholly-owned Hong Kong Operating Subsidiaries, MS (HK) Engineering Limited and MS Engineering Co., Limited. It is engaged in wet trades works, such as plastering works, tile laying works, brick laying works, floor screeding works and marble works. the company is mainly engaged in private-sector projects in Hong Kong. Its private sector projects mainly involve private residential developments and commercial developments. The project owners of its private sector projects are generally property developers, and its customers are generally main contractors and wet trades work subcontractors engaged under such projects.

Share on Social Networks: